FUS | LEEP | X2 | P | ||
---|---|---|---|---|---|
3–6 months | |||||
Over all participants followed up | 101 | 124 | |||
no evidence of disease | 90(89.11%) | 117(94.35%) | 2.970 | 0.085 | |
HPV-positive at baseline participants followed up | 97 | 122 | |||
clearance of HPV | 72(74.23%) | 101(82.79%) | 2.386 | 0.122 | |
6–12 months | |||||
No evidence of disease at 3-6month follow-up participants followed up | 90 | 117 | |||
recurrent disease | 2(2.22%) | 2(1.71%) | 0.071 | 0.790 | |
HPV-positive at baseline participants followed up | 93 | 120 | |||
clearance of HPV | 79(84.95%) | 107(89.17%) | 0.843 | 0.359 |